Gene: TRA2A
Official Full Name: transformer 2 alpha homologprovided by HGNC
Gene Summary: This gene is a member of the transformer 2 homolog family and encodes a protein with several RRM (RNA recognition motif) domains. This phosphorylated nuclear protein binds to specific RNA sequences and plays a role in the regulation of pre-mRNA splicing. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Sep 2013]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO26979 | TRA2A Knockout cell line (HeLa) | Human | TRA2A | 1:3~1:6 | Negative | Online Inquiry |
KO26980 | TRA2A Knockout cell line (HCT 116) | Human | TRA2A | 1:2~1:4 | Negative | Online Inquiry |
KO26981 | TRA2A Knockout cell line (HEK293) | Human | TRA2A | 1:3~1:6 | Negative | Online Inquiry |
KO26982 | TRA2A Knockout cell line (A549) | Human | TRA2A | 1:3~1:4 | Negative | Online Inquiry |
TRA2A Gene Knockout Cell Lines are specifically engineered cellular models that have had the TRA2A gene selectively disrupted, providing researchers with a powerful tool for studying gene function and related biological pathways. TRA2A, or transformer 2 alpha, is a splicing factor that plays a critical role in the regulation of alternative splicing, influencing the diversity of protein expression in a cellular context. By removing the functionality of the TRA2A gene, these knockout cell lines enable scientists to dissect the complexities of splicing mechanisms and their implications in various cellular processes.
The inherent value of TRA2A Gene Knockout Cell Lines lies in their precise ability to elucidate the consequences of TRA2A deficiency on cellular function, gene expression profiles, and developmental processes. Researchers can utilize these models to explore TRA2A’s involvement in diseases where alternative splicing plays a pivotal role, such as cancer and neurodegenerative disorders. This understanding can inform new therapeutic strategies or the development of biomarkers for disease progression.
One of the key advantages of TRA2A Gene Knockout Cell Lines over traditional models is their specificity and reliability. Unlike transient knockdown methods, which can suffer from incomplete gene silencing and variability, these knockout lines provide stable, reproducible results crucial for long-term experimental validity. Furthermore, the accessibility of these cell lines allows for high-throughput screening and drug discovery initiatives, enabling rapid innovation in therapeutic approaches.
For researchers and clinicians seeking to deepen their understanding of gene function, alternative splicing, or the molecular underpinnings of disease, TRA2A Gene Knockout Cell Lines offer an invaluable resource. Our company specializes in delivering high-quality and meticulously characterized biological products tailored to support cutting-edge research and clinical endeavors, ensuring excellence and reliability in every aspect of our offerings.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.